172 related articles for article (PubMed ID: 35192058)
41. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
42. Clinical outcomes of advanced stage cancer patients treated with sequential immunotherapy in phase 1 clinical trials.
Martini DJ; Liu Y; Shabto JM; Lewis C; Kline MR; Collins H; Akce M; Kissick HT; Carthon BC; Shaib WL; Alese OB; Pillai RN; Steuer CE; Wu CS; Lawson DH; Kudchadkar RR; Master VA; El-Rayes BF; Ramalingam SS; Owonikoko TK; Harvey RD; Bilen MA
Invest New Drugs; 2019 Dec; 37(6):1198-1206. PubMed ID: 30725388
[TBL] [Abstract][Full Text] [Related]
43. Impact of timing and setting of palliative care referral on quality of end-of-life care in cancer patients.
Hui D; Kim SH; Roquemore J; Dev R; Chisholm G; Bruera E
Cancer; 2014 Jun; 120(11):1743-9. PubMed ID: 24967463
[TBL] [Abstract][Full Text] [Related]
44. Effect of corticosteroids on the outcome of patients with advanced non-small cell lung cancer treated with immune-checkpoint inhibitors.
Skribek M; Rounis K; Afshar S; Grundberg O; Friesland S; Tsakonas G; Ekman S; De Petris L
Eur J Cancer; 2021 Mar; 145():245-254. PubMed ID: 33419647
[TBL] [Abstract][Full Text] [Related]
45. Prevalence of systemic anticancer therapy for patients within the last 30 days of life: experience in a private hospital oncology group.
Wein L; Rowe C; Brady B; Handolias D; Lipton L; Pook D; Stanley R; Haines I
Intern Med J; 2017 Mar; 47(3):280-283. PubMed ID: 27658500
[TBL] [Abstract][Full Text] [Related]
46. Combined Immunotherapy and Stereotactic Radiotherapy Improves Neurologic Outcomes in Patients with Non-small-cell Lung Cancer Brain Metastases.
Enright TL; Witt JS; Burr AR; Yadav P; Leal T; Baschnagel AM
Clin Lung Cancer; 2021 Mar; 22(2):110-119. PubMed ID: 33281062
[TBL] [Abstract][Full Text] [Related]
47. Administration of Immune Checkpoint Inhibitors Near the End of Life.
Bloom MD; Saker H; Glisch C; Ramnaraign B; George TJ; Markham MJ; Kelkar AH
JCO Oncol Pract; 2022 Jun; 18(6):e849-e856. PubMed ID: 35254868
[TBL] [Abstract][Full Text] [Related]
48. Survival benefit from immunocheckpoint inhibitors in stage IV non-small cell lung cancer patients with brain metastases: A National Cancer Database propensity-matched analysis.
Takamori S; Komiya T; Powell E
Cancer Med; 2021 Feb; 10(3):923-932. PubMed ID: 33340271
[TBL] [Abstract][Full Text] [Related]
49. Impact of bowel movement condition on immune checkpoint inhibitor efficacy in patients with advanced non-small cell lung cancer.
Katayama Y; Yamada T; Tanimura K; Yoshimura A; Takeda T; Chihara Y; Tamiya N; Kaneko Y; Uchino J; Takayama K
Thorac Cancer; 2019 Mar; 10(3):526-532. PubMed ID: 30666802
[TBL] [Abstract][Full Text] [Related]
50. Trends of Utilization of Palliative Care and Aggressive End-of-Life Care for Patients Who Died of Cancers and Those Who Died of Noncancer Diseases in Hospitals.
Ko YT; Ko MC; Huang CM; Lien HY; Woung LC; Huang SJ
J Pain Symptom Manage; 2020 Dec; 60(6):1136-1143. PubMed ID: 32619671
[TBL] [Abstract][Full Text] [Related]
51. Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors.
Suresh K; Voong KR; Shankar B; Forde PM; Ettinger DS; Marrone KA; Kelly RJ; Hann CL; Levy B; Feliciano JL; Brahmer JR; Feller-Kopman D; Lerner AD; Lee H; Yarmus L; D'Alessio F; Hales RK; Lin CT; Psoter KJ; Danoff SK; Naidoo J
J Thorac Oncol; 2018 Dec; 13(12):1930-1939. PubMed ID: 30267842
[TBL] [Abstract][Full Text] [Related]
52. Switching administration of anti-PD-1 and anti-PD-L1 antibodies as immune checkpoint inhibitor rechallenge in individuals with advanced non-small cell lung cancer: Case series and literature review.
Kitagawa S; Hakozaki T; Kitadai R; Hosomi Y
Thorac Cancer; 2020 Jul; 11(7):1927-1933. PubMed ID: 32421224
[TBL] [Abstract][Full Text] [Related]
53. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
54. Duration of palliative care involvement and cancer care aggressiveness near the end of life.
Monier PA; Chrusciel J; Ecarnot F; Bruera E; Sanchez S; Barbaret C
BMJ Support Palliat Care; 2020 Dec; ():. PubMed ID: 33355165
[TBL] [Abstract][Full Text] [Related]
55. The Palliative Prognostic (PaP) Score without Clinical Evaluation Predicts Early Mortality among Advanced NSCLC Patients Treated with Immunotherapy.
De Giglio A; Tassinari E; Zappi A; Di Federico A; Lenzi B; Sperandi F; Melotti B; Gelsomino F; Maltoni M; Ardizzoni A
Cancers (Basel); 2022 Nov; 14(23):. PubMed ID: 36497326
[TBL] [Abstract][Full Text] [Related]
56. Raising awareness of immune-related side effects in oncological patients under palliative care: a report of two cases.
Strunk A; Batzler YN; Ziemer M; Neukirchen M; Schwartz J; Sachse M; Garzarolli M; Strasser C; Reinhardt L; Kaatz M; Schuler U; Meier F
Ann Palliat Med; 2023 Jul; 12(4):826-833. PubMed ID: 37038066
[TBL] [Abstract][Full Text] [Related]
57. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
58. Antibiotic prescription patterns during last days of hospitalized patients with advanced cancer: the role of palliative care consultation.
Kim JH; Yoo SH; Keam B; Heo DS
J Antimicrob Chemother; 2023 Jul; 78(7):1694-1700. PubMed ID: 37220755
[TBL] [Abstract][Full Text] [Related]
59. Effect of early palliative care on chemotherapy use and end-of-life care in patients with metastatic non-small-cell lung cancer.
Greer JA; Pirl WF; Jackson VA; Muzikansky A; Lennes IT; Heist RS; Gallagher ER; Temel JS
J Clin Oncol; 2012 Feb; 30(4):394-400. PubMed ID: 22203758
[TBL] [Abstract][Full Text] [Related]
60. The impact of the duration of the palliative care period on cancer patients with regard to the use of hospital services and the place of death: a retrospective cohort study.
Hirvonen OM; Leskelä RL; Grönholm L; Haltia O; Voltti S; Tyynelä-Korhonen K; Rahko EK; Lehto JT; Saarto T
BMC Palliat Care; 2020 Mar; 19(1):37. PubMed ID: 32209075
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
